论文部分内容阅读
目的探讨非霍奇金淋巴瘤合并糖尿病患者的激素使用问题。方法对40例合并糖尿病的非霍奇金淋巴瘤患者用含泼尼松(PDN)的方案进行化疗,比较使用PDN前后的血糖变化,调整降糖药物,同时观察并发症。结果患者入院时空腹血糖(6.1±1.3)mmol/L,化疗后血糖(6.5±1.2)mmol/L,化疗前后血糖比较差异无统计学意义;化疗过程中降糖药用量略增加;所有患者无并发症发生。结论在有效控制血糖的情况下,非霍奇金淋巴瘤合并糖尿病的患者可常规使用PDN。
Objective To investigate the use of hormones in patients with non-Hodgkin’s lymphoma and diabetes mellitus. Methods Forty patients with non-Hodgkin’s lymphoma with diabetes were treated with prednisone (PDN). The blood glucose changes before and after PDN were compared. The hypoglycemic drugs were adjusted and the complications were observed. Results The fasting blood glucose (6.1 ± 1.3) mmol / L and the post-chemotherapy blood glucose (6.5 ± 1.2) mmol / L were not significantly different between before and after chemotherapy. The dosage of hypoglycemic drugs slightly increased in all patients No complications occurred. Conclusions PDN is routinely used in patients with non-Hodgkin’s lymphoma and diabetes mellitus with effective glycemic control.